Australia Dermatology Drugs Market

Australia Dermatology Drugs Market
Analysis
A sample report on

This report presents a strategic analysis of the Australia Dermatology
Drug Market and a forecast for its development in the medium and
long term. It provides a comprehensive overview of the market value,
dynamics, segmentation, main players, growth and demand drivers,
challenges & future outlook, etc. This is one of the most comprehensive
reports about the Australia Dermatology Drug Market, and offers
unmatched value, accuracy, and expert insights.

3
A Sample Report on Australia Dermatology Drug Market Analysis I Confidential
Report Attribute Details
Number of Pages 70-80
Base Year for Estimation 2022
Forecast Period 2023-2030
Report Coverage
Market Overview, Revenue Forecast, Market Segmentation, Growth Factors and Trends,
Competitive Landscape, Key Company Profiles, Government Policies, Regulatory Landscape,
Reimbursement Scenario
Quantitative Units Revenue in USD Million/Billion (Mn/Bn)
Research Approach Secondary Research (60%), Primary Research (40%)
Click on the icon to know the detailed methodology
Report Scope

4
CONTENT PG. NO.
1. Dermatology Drug Market Overview 07-20
1.1. Global Overview
1.2. Australia Overview
1.3. Economic Overview: Australia
1.4. The Burden of Skin Disease in Australia
1.5 Major Dermatological Diseases: Australia
1.6. Psoriasis Overview
1.7. Treatment Pathway for psoriasis
1.8. Dermatology Drug Market in Australia
1.9. Healthcare Scenario in Australia
1.10. Budget of Australia Government for Public Insurance
1.11. Mergers and Acquisitions
2. Market Size and Forecasting 21-28
2.1. Market size and forecasts (Excel and Methodology)
2.2. Market Segmentation
2.2.1. By Drug Class
Table of Content

5
CONTENT PG. NO.
2.2.2. By End User
2.2.3. By Application
2.2.4. By Distribution Channel
3. Market Dynamics 29-34
3.1. Market Growth Drivers
3.2. Market Restraints
4. Competitive Landscape 35-43
4.1. Key Company Profile
4.1.1. Pfizer
4.1.2. XX
4.1.3. XX
4.1.4. XX
4.1.5. XX
4.1.6. XX
Table of Content

6
CONTENT PG. NO.
4.1.7. XX
4.1.8. XX
4.1.9. XX
4.1.10. XX
5. Reimbursement Scenario 44-47
5.1. Reimbursement Regulation in Australia
5.2. Reimbursement Process
6. Methodology & Scope 48-69
Table of Content

Australia Dermatology Drug Market Analysis
1. Market Overview

8
1.1 Statistics at a Glance: The Scenario of Skin Disease in the World (1/2)
Scope of Dermatology Drugs ▪ Please be aware that this sample report is
intended to provide you with a brief
overview of the kind of information and
analysis that will be presented in the final
report
▪ In this section you will get an
understanding of the topic, which includes
the prevalence of the disease, the
application of medical devices, new
technology, and other details related to the
topic
▪ In order to obtain access to all of the
information that you are seeking, you will
need to purchase the final report
▪ Final report will be comprehensive and
detailed, and it will include data, analysis,
trends, and other relevant information
related to the topic or subject matter of
interest
900 Mn
People worldwide
are affected by skin
disease
$35.2 Bn
Is the annual healthcare
burden of psoriasis in USA
125 Mn
People worldwide
suffer from psoriasis
$75 Bn
Is the annual healthcare
cost of skin disease in
USA
80 %
Of all skin disease
can be attributed to 5
common conditions
4.6 Mn
Incident cases of psoriasis
globally in 2019
Illustrative

9
1.1 Statistics at a Glance: The Scenario of Skin Disease in the World (2/2)
North America
~ Market Size of
$XX Bn
Europe
~Revenue to reach
$XX Bn by 2027
Asia
-Fastest CAGR
Africa
~Market Size of
$XX Bn
Australia Market
~$xx Mn Market
Illustrative

10
1.2 Australia Overview
54 Mn
Is the population of
Australia, in 2021
32 Years
Is the median age
in Australia, in
2021
$2.25 Tn
is the Gross
Domestic Product
(GDP) of Australia in
2021
$9365
Average per capita
healthcare expenditure
in Australia in 2021
▪ Please be aware that this sample report is
report
understanding of the demographics of the
country/region, which includes the
population, GDP, healthcare expenditure
and other details related to the topic
interest
Illustrative

11
1.3 Economic Overview: Australia
XX
XX
2020 2021 2022 2023F 2024F 2025F 2026F 2027F 2028F 2029F 2023F
Population of Australia, (2020-2030)
XX
XX
2020 2021 2022 2023F 2024F 2025F 2026F 2027F 2028F 2029F 2023F
GDP of Australia, (2020-2030)
Population Split (2023)
Male
51%
Female
49%
By Gender By Age Group
0-14
15-24
25-54
55-64
65+
▪ In this section you will get an understanding of the demographics
of the country/region, which includes the population, GDP,
healthcare expenditure and other details related to the topic
▪ In order to obtain access to all of the information that you are
seeking, you will need to purchase the final report
▪ Final report will be comprehensive and detailed, and it will
include data, analysis, trends, and other relevant information
related to the topic or subject matter of interest
Illustrative

12
1.4 Statistics at a Glance: The Burden of Skin Disease in Australia
Overview of Skin Disease
▪ Please be aware that this sample report
is intended to provide you with a brief
analysis that will be presented in the
final report
understanding of the topic, which
includes the prevalence of the disease,
the application of medical devices, new
technology, and other details related to
the topic in Australia
information that you are seeking, you
will need to purchase the final report
detailed, and it will include data,
analysis, trends, and other relevant
information related to the topic or
subject matter of interest
1 Mn
People in Australia,
suffer from a long-
term skin condition
2000 +
Deaths due to skin
disease in Australia per
year
4.4%
Average prevalence of psoriasis
in Australia in 2021
$241 Bn
Total national health
expenditure in 2021
$9365
Average per capita
healthcare
expenditure in 2021
31%
Population visit
dermatologist for treatment
of skin disease
Illustrative

13
1.5 Major Dermatological Diseases: Australia
Illustrative
Skin Cancer
▪ Australia has one of the highest
incidences of skin cancer globally, with
more than 750,000 individuals
receiving treatment for this condition
annually.
Atopic Dermatitis
▪ This is a prevalent skin condition
characterized by dry, itchy, and inflamed skin
▪ In the general practice setting in Australia, the
approximate lifetime prevalence of atopic
dermatitis was recorded at 16.4%
Psoriasis
▪ This refers to a persistent autoimmune
disorder characterized by the
development of red and scaly patches
on the skin
▪ 4.4% is the average prevalence of
psoriasis in Australia in 2021
Acne
▪ This is a widespread skin condition
that arises when hair follicles get
blocked with a combination of oil and
dead skin cells
▪ Prevalence of physician diagnosed
acne is 12.8%
Major
Dermatological
Diseases

14
1.6 Psoriasis Overview
▪ Psoriasis is a persistent autoimmune disorder that primarily affects the skin, resulting in the development of red, raised patches covered
with silvery scales
▪ It is caused by an overactive immune system that accelerates the skin's cell turnover process, leading to the rapid accumulation of skin
cells on the surface and the formation of characteristic lesions
▪ It not only affects the skin but can also involve nails and joints, potentially leading to conditions like psoriatic arthritis with joint pain and
swelling
▪ Red, Raised Patches: Elevated red patches on the skin
▪ Silvery Scales: Scales covering the red patches
▪ Dry, Cracked Skin: Potential dryness, leading to bleeding.
▪ Itching or Burning: Common sensations in affected areas
▪ Stiff and Swollen Joints: Possible joint stiffness (psoriatic
arthritis)
▪ Nail Abnormalities: Thickened, pitted, or ridged nails.
▪ Soreness or Discomfort: Accompanies psoriasis lesions.
▪ Nail Discoloration or Separation: Affects nails, causing
discoloration or separation
▪ Specific Lesion Areas: Commonly seen on the scalp,
elbows, knees, and lower back
Signs and Symptoms
▪ Plaque Psoriasis: Common type, raised red patches with
silvery scales
▪ Guttate Psoriasis: Small, dot-like lesions, often triggered by
infections
▪ Inverse Psoriasis: Smooth, red lesions in skin folds
▪ Pustular Psoriasis: White blisters with pus, on hands or
feet
▪ Erythrodermic Psoriasis: Rare, widespread redness,
severe itching, skin shedding
▪ Psoriatic Arthritis: Joint pain, stiffness, swelling in some
with psoriasis
▪ Nail Psoriasis: Affects nails, causing pitting, discoloration,
abnormal growth
Types
Illustrative

15
1.7 Treatment Pathway for Psoriasis
Psoriasis Diagnosis &
Disease Assessment
Localized Treatment
OTC topical
Localized steroids
Localized Phototherapy
Generalized Treatment
Disease controlled
Treatment
Adherence
Ensure Optimal
Adherence
No Improvement
Continue Localized
Treatment
Skip Non-biologics:
inadequate treatment
response
negative impact on
quality of life
Biologics and/or
Phototherapy
Non-biologics
Biologics
Phototherapy
Non-biologics
Biologics
Skip phototherapy:
financial
constraints
inconvenience
non-responsive
Mild Psoriasis
BSA ≤ 10%
Moderate to severe
Psoriasis
BSA > 10%
Illustrative

16
1.8 Dermatology Drug Market in Australia
2022 2023F 2024F 2025F 2026F 2027F 2028F 2029F 2030F
Australia Dermatology Drug Market Forecast, 2022-2030 (in $Bn)
▪ Please be aware that this sample report is intended to provide you with a brief overview of the kind of information and analysis that will be
presented in the final report
▪ In this section you will get an understanding of the overall Categoryname market in Australia, which includes the market size, current trends
and other details related to the topic
▪ In order to obtain access to all of the information that you are seeking, you will need to purchase the final report
▪ Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic or
subject matter of interest
Illustrative

17
1.9 Healthcare Scenario in Australia
Dermatology Drug Development Process: The process of developing a Dermatology drug is complex and involves many stages, from
preclinical research to clinical trials to regulatory approval. Here is a simplified diagram of the Dermatology drug development process:
o Preclinical Research: Researchers identify potential drug candidates and test them in the lab
o Phase 1 Clinical Trials: Small studies are conducted to test the safety and dosage of the drug in humans
o Phase 2 Clinical Trials: Larger studies are conducted to test the effectiveness of the drug in treating Dermatology
o Phase 3 Clinical Trials: Even larger studies are conducted to compare the new drug to standard treatments and evaluate its safety and
effectiveness
o Regulatory Approval: The drug is reviewed by regulatory agencies such as the TGA and approved for use in the Australia market
Fast Track
▪ Fast track is a process designed to facilitate the development, and expedite the review of drugs to treat
serious conditions and fill an unmet medical need
Breakthrough
Therapy
▪ A process designed to expedite the development and review of drugs which may demonstrate substantial
improvement over available therapy
Accelerated
Approval
▪ These regulations allowed drugs for serious conditions that filled an unmet medical need to be approved
based on a surrogate endpoint
Priority Review ▪ A Priority Review designation means TGA’s goal is to take action on an application within 6 months
TGA has developed several approaches to making drugs available as quickly as possible, while still ensuring their safety and
effectiveness. Here are four of these approaches:
Illustrative

18
1.10. Budget of Australia Government for Public Insurance
Proposed Budget By Category
Outlays 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2022-31
In Billions Of Dollars
Public $769 $709 $766 $841 $840 $947 $1,014 $1,085 $1,227 $1,178 $1,325 $1,412 $10,633
Private $458 $521 $571 $582 $616 $645 $674 $698 $734 $768 $801 $837 $6,926
As % Of GDP
Public 3.7% 3.2% 3.3% 3.4% 3.3% 3.6% 3.7% 3.8% 4.1% 3.8% 4.1% 4.2% 3.7%
Private 2.2% 2.4% 2.4% 2.4% 2.4% 2.4% 2.4% 2.4% 2.5% 2.5% 2.5% 2.5% 2.4%
▪ National Health Expenditures (NHE) grew 2.7% to $4.3 trillion in 2021, or $12,914 per person, and accounted for 18.3% of Gross Domestic Product (GDP)
▪ Public spending grew 8.4% to $900.8 billion in 2021, or 21% of total NHE
▪ Private spending grew 9.2% to $734.0 billion in 2021, or 17% of total NHE
▪ Private health insurance spending grew 5.8% to $1,211.4 billion in 2021, or 28% of total NHE
▪ Out of pocket spending grew 10.4% to $433.2 billion in 2021, or 10% of total NHE
▪ Other Third Party Payers and Programs and Public Health Activity spending declined 20.7% in 2021 to $596.6 billion, or 14% of total NHE
▪ Hospital expenditures grew 4.4% to $1,323.9 billion in 2021, slower than the 6.2% growth in 2020
▪ Physician and clinical services expenditures grew 5.6% to $864.6 billion in 2021, slower growth than the 6.6% in 2020
▪ Prescription drug spending increased 7.8% to $378.0 billion in 2021, faster than the 3.7% growth in 2020
▪ Largest shares of total health spending were sponsored by the federal government (34%) and the households (27%). The private business share of health
spending accounted for 17% of total health care spending, state and local governments accounted for 15%, and other private revenues accounted for 7%
Illustrative

19
1.11. Mergers and Acquisitions (continued)
Company Name Type
Amount /
Duration
Year Key Pointers
Merger of PharmaLex with
Cpharm
Merger NA April, 2023
▪ PharmaLex's merger with Cpharm: PharmaLex, a leading
provider of specialized services for the pharma, biotech, and
medtech industries, announced its intention to merge with
Cpharm, a leading provider of pharmacovigilance and medical
services in Australia and New Zealand
▪ Cpharm, located in New South Wales, Australia, specializes in
delivering pharmacovigilance and medical services to clients in
Australia and New Zealand.
▪ PharmaLex specializes in offering specialized services to the
pharmaceutical, biotech, and medtech sectors.
Latest Deals In Australia
Illustrative

20
1.11. Mergers and Acquisitions (continued)
Company Name Type
Amount /
Duration
Year Key Pointers
Merger March 2023
Merger Jan 2023
Latest Deals In Australia

2. Market Size and Forecasting

22
intended to provide you with a brief overview
of the kind of information and analysis that
will be presented in the final report
▪ In this section you will get an understanding
of the overall market, which includes the
market size, current trends and other details
related to the topic
trends, and other relevant information related
to the topic or subject matter of interest
XX
XX
2022 2023F 2024F 2025F 2026F 2027F 2028F 2029F 2030F
Australia Dermatology Drug Market Forecast, 2022-2030
Click on the icon to know the
methodology and assumption
2023 2024 2025 2026 2027 2028 2029 2030
Major Markets Patient
($Mn)
2.74 2.82 2.90 2.94 2.98 3.02 3.07 3.12
Australia Patient Size
($Bn)
0.51 0.61 0.68 0.69 0.70 0.71 0.72 0.73
% of Patients 18.75% 21.70% 23.56% 23.45% 23.42% 23.39% 23.34% 23.45%
Global Market Size ($Bn) 3,620 3,780 3,950 4,128 4,314 4,508 4,711 4,937
Australia Market Size
($Bn)
61 74 84 87 91 95 99 106
Illustrative
2.1 Market size and forecasts (Excel and Methodology)

23
▪ In this section you will get an understanding of the segmentations which will cover the Australia Dermatology Drug Market
▪ In order to obtain access to all of the information that you are seeking, you will need to purchase the final report
Application
Psoriasis
Lichen Sclerosis
Atopic Dermatitis
(Eczema)
Acne
Skin Dermatology
Fungal Infection
Distributions Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Illustrative
2.2 Snapshot of Dermatology Drug Market Segmentation
Drug Class
Anti-infectives
Corticosteroids
Retinoids
Antirheumatic
Calcineurin inhibitors
End User
Home Care
Hospital
Dermatology Clinics

24
Illustrative
2.2.1 Market Segmentation: By Drug Class
Australia Dermatology Prescriptions Products Market Share Analysis (US$ Mn)
34.5
45.2
58.2
63.7
70.1
74.8
53.4
58.1
63.2
68.9
75.3
82.3
42.1
45.5
55.2
63.2
71.4
78.1
12.0
15.5
19.3
23.5
28.3
33.5
25.6
28.5
31.7
35.2
39.1
43.5
Anti-infective Corticosteroids Retinoids Antirheumatic Calcineurin Inhibitors

25
Dermatology Drug Market Share, By End User(2022)
▪ Homecare is the largest segment for
Dermatology Drug in Australia and it had a
market value of more than 40% in 2022
▪ Use of Dermatology Drug is growing
rapidly due to factors the high prevalence
of Dermatology and the availability of a
large number of Dermatology Drug for
treatment
report
Illustrative
2.2.2 Market Segmentation: By End User
Homecare
Hospital
Dermatology
Clinics

26
Dermatology Drug Market Share, By Application
(2022)
▪ Psoriasis is the largest segment for
Dermatology Drug in Australia and it had a
market value of more than 40% in 2022
▪ Use of Dermatology Drug is growing
rapidly due to factors the high prevalence
of Dermatology and the availability of a
large number of Dermatology Drug for
treatment
report
Illustrative
2.2.3 Market Segmentation: By Application
Psoriasis
Eczema
Fungal Infection
Acne
Skin Cancer
Lichen Sckerosis

27
Dermatology Drug Market Share, By Distribution Channel
(2022)
▪ Most commonly used distribution channel
for Dermatology Drug is Retail
pharmacies, as Dermatology Drug are
usually administered in hospitals making it
convenient for patients to procure them
from the hospital pharmacy
report
interest
Illustrative
2.2.4 Market Segmentation: By Distribution Channel
Hospital
Pharmacies
Retail
Pharmacies
Online
Pharmacies

3. Market Dynamics

29
3.1 Market Growth Drivers
▪ Australian Government has introduced a multi-million-dollar
campaign, "Slip, Slop, Slap, Seek and Slide," aiming to reduce the
prevalence of skin cancer in Australia. Skin cancer is recognized
as a widespread, expensive, and avoidable form of cancer in the
country
▪ Skin Cancer Prevention Campaigns in New South Wales (NSW):
The Cancer Institute NSW has been conducting public education
initiatives since 2005 to mitigate skin cancer incidence across the
state. These campaigns aim to shift public attitudes towards sun
safety
▪ SunSmart Tradie Toolbox initiative, a collaboration between the
Cancer Council and the Australian Government, focuses on
educating and encouraging tradespeople to prioritize sun safety.
The campaign aims to increase awareness within the industry
regarding the significance of sun protection
3.1.1 Different initiatives to increase awareness regarding skin disease , will increase the demand for Dermatology
Drugs
Illustrative
2018 2019 2020 2021
Initiatives in Dermatology in Australia

30
3.1 Market Growth Drivers (continued)
3.1.2 Rising prevalence of skin disease will lead to increased demand for Dermatology medications
Illustrative
Prevalence of Diseases in Dermatology in
Australia
▪ Increasing prevalence of diverse skin disorders in Australia is a
public health issue, as underscored by numerous studies
▪ Psoriasis has a notable prevalence in Australia, impacting 4.4% of
the population. It is more frequently observed in adults, with an
estimated lifetime prevalence of 2.38% as diagnosed by
physicians.
▪ As per a study involving Australian school students, the general
occurrence of atopic dermatitis (AD) was 16.3%, demonstrating
higher rates in girls compared to boys
▪ Dry skin, or xerosis, was the most prevalent condition, impacting
29.5% of patients, followed by onychomycosis (tinea unguium) at
22.5%, and dermatitis at 8.9%
▪ Furthermore, there has been a yearly rise of up to 6% in the
occurrence of skin cancer, particularly non-melanoma skin
cancers, over the last three decades

31
▪ In the fiscal year 2020–21, Australia allocated around $220.9
billion for healthcare expenditures, translating to an average
spending of approximately $8,617 per individual, as reported by
the Australian Institute of Health and Welfare
▪ Furthermore, during the 2021–22 fiscal year, Australia's
expenditure on health goods and services amounted to an
estimated $241.3 billion, averaging around $9,365 per person
▪ The actual increase in overall health spending, adjusted for
inflation, was XX % higher than the figures reported for 2020–
2021
3.1.3 Increase in Public Healthcare Spending, will increase the demand for Dermatology Drugs
Illustrative
XX $
XX $
2020 2021
National Healthcare Expenditure in
Australia

32
▪ Disease like psoriasis, eczema are more common in geriatric
population
▪ Aging of Australia's population is a result of rising life
expectancy and decreasing fertility rates
▪ Population of older Australians, aged 65 and above, rose from
1.0 million (constituting 8.3% of the total population) in 1970 to
2.1 million (12%) in 1995, and this trend is projected to persist
with further growth
▪ Australia anticipates an increase in life expectancy, projecting
a threefold rise in the population aged over 85 in the coming
decades, alongside a doubling of the over-65 demographic
3.1.4 Geriatric population is set to increase 3 Fold in upcoming decade
Illustrative
XX %
XX %
XX %
XX %
2020 2021 2022 2023
Growing Geriatric Population

33
3.2.1 High treatment cost
▪ High development costs and the
need for ongoing research can
result in high pricing for
dermatology drugs. Healthcare
systems, insurers, and patients
may resist high costs, leading to
pricing pressures and limited
market penetration
▪ The average healthcare
expenditure per capita in 2021
amounted to $9365
▪ Average healthcare cost for skin
cancer is around $11,000
3.2.2 Competition from generic
drug market
▪ In Australia, approximately 25%
of prescriptions submitted to
pharmacists are fulfilled with
generic medications, highlighting
a substantial reliance on non-
brand-name drugs within the
pharmaceutical landscape of the
country
▪ Generic drugs constituted over
15% of the total expenditure
within the Pharmaceutical
Benefits Scheme (PBS) in
Australia, underscoring a
significant financial allocation
toward non-brand-name
pharmaceuticals within the
national healthcare framework.
3.2.3 Regulatory Hurdles
▪ Therapeutic Goods Administration
(TGA) oversees the quality,
supply, and promotion of
medications in Australia
▪ Setting prices and securing
reimbursement for their products
poses challenges for companies in
Australia, with the Pharmaceutical
Benefits Advisory Committee
(PBAC) playing a crucial role in
pricing process
▪ In terms of approval times,
Australia falls in the middle range
among global regulators, with a
pace slower than the US Food
and Drug Administration (FDA)
Our analysis will thoroughly investigate the key restraints that may significantly impact business
operations and growth.
Illustrative
3.2 Market Restraints

4. Competitive Landscape

35
Key Note:
Pfizer
1
Mayne Pharma
(Foulding)
6
Sanofi
2 Arrotex
7
LEO Pharma
3 AFT Pharmaceuticals
8
Roche
4
Neuren
Pharmaceuticals
9
AbbVie
5
Clarity
Pharmaceuticals
10
▪ Here is the list of top 10 companies which
will cover in the final report
▪ Each company will have slides for
o Overview
o Key details
o Offerings
o Name of products
o Recent activities/ Press Coverage
o Distribution and Vendor Partners
o Mergers, Acquisitions and
Collaboration
o Financials (As per availability)
▪ If there are specific companies that you
would like to be included in the report, please
let us know via email
4.1 Key Players in Australia Dermatology Drug Market
Illustrative
MNCs Local Companies

36
4.1.1 Pfizer
Founded in: 1849
HQ: New York, USA
Type: Private
Revenue: $100.3 Bn (global)
Website: www.pfizer.com
▪ Pfizer is a leading global pharmaceutical company which is one of
the dominant player in the Australia
▪ It is committed to developing and commercializing premium
medicines which are safe, effective as well as affordable
▪ Pfizer's research and development costs for the twelve months
ending September 30, 2023, rose by 1.97% compared to the
previous year, reaching $11.480 billion
Solutions offered
➢ Diagnostics
➢ Biologics and Dermatology Drug
➢ Pharmaceuticals
➢ Veterinary products
Some of the Dermatology Drug offered by Pfizer
Tofacitinib Treatment for adults with moderate to
severe plaque psoriasis
CIBINQO® (abrocitinib) Treatment of moderate-to-severe
atopic dermatitis
ABRILADA™ (adalimumab-afzb) Treatment of psoriasis and psoriatic
arthritis
Etanercept (Enbrel) Treatment of psoriasis and psoriatic
arthritis
Oct 2023: Pfizer has recently received FDA approval for its
Dermatology Drug ABRILADA™, which is one of only two
Dermatology Drug that are interchangeable with Humira®
Oct 2023:Pfizer Australia and BioNTech have received approval
from the Therapeutic Goods Administration (TGA) for their
monovalent COVID-19 vaccine adapted to the Omicron XBB.1.5
variant
Illustrative
Recent Activity / Press Coverage

37
4.1.1 Pfizer (continued)
Company Name Type
Amount /
Duration
Year Key Pointers
Seagen Inc.
Acquisition $43 Bn Mar, 2023
▪ Pfizer announced that it would acquire Seagen, a global
biotechnology company that discovers, develops, and
commercializes transformative Dermatology medicines
▪ This acquisition is expected to enhance Pfizer's position the
segment of Oncology, with Seagen's medicines, late-stage
development programs, and pioneering expertise in Antibody-
Drug Conjugates (ADCs) strongly complementing Pfizer's
Oncology portfolio
Arena
Pharmaceuticals
Acquisition $6.7 Bn Mar, 2022
▪ Pfizer acquired Arena Pharmaceuticals, a clinical-stage startup
creating novel potential treatments for the treatment of various
immuno-inflammatory illnesses
▪ This acquisition granted Pfizer access to Arena's portfolio of
potential treatments for the fields of gastrointestinal, dermatology,
and cardiology
Latest Deals - Mergers and Acquisitions
Illustrative

38
2020 2021 2022 2023F 2024F 2025F 2026F 2027F 2028F 2029F 2030F
4.1.1 Pfizer (continued)
Revenues ($Bn), 2020-2030
report
▪ In this section you will the understating of
financial overview of the company, which
includes revenue forecasting, segment
revenue and other key details as per
availability
interest
Breakdown of Net Revenue by Segment, 2023
1 2 3 4
Illustrative

39
4.1.2 Company 2
Founded in:
HQ:
Type:
Revenue:
Website:
Solutions offered by Company
Drugs Indications
Dermatology
Drug Products
Recent Activity / Press Coverage

40
4.1.2 Company 2 (continued)
Major Distribution Partners Major Vendor Partners
Partnerships Ecosystem

41
Company Name Type
Amount /
Duration
Year Key Pointers
Latest Deals - Mergers and Acquisitions

42
xx xx xx
2020 2021 2022 2023F 2024F 2025F 2026F 2027F 2028F 2029F 2030F
Revenues ($Bn), 2020-2030
report
▪ In this section you will the understating of
financial overview of the company, which
includes revenue forecasting, segment
revenue and other key details as per
availability
interest
Breakdown of Net Revenue by Segment, 2022
1 2 3 4

5. Reimbursement Scenario

44
5.1 Reimbursement Regulation for Dermatology Drug in Australia
Coverage Penetration (% Total Population) Source of Funding
Spend on Healthcare (%of Current Health Expenditure)
Reimbursement Market Trends
 Public healthcare coverage is provided by the government and includes
various programs
▪ Shift towards value-based care has been a significant trend in Australia healthcare system, with payers and providers increasingly focused on improving patient
outcomes and reducing costs
▪ This has led to the development of alternative payment models such as accountable care organizations (ACOs) and bundled payment arrangements, which
incentivize providers to deliver high-quality, cost-effective care 38.9%
37.1%
35.6%
32.5%
31.5%
44.0%
46.0%
47.7%
51.0%
51.8%
2017 2018 2019 2020 2021 2022 2023
Government Expenditure
Private Health Insurance
Out of Pocket
Other
NA NA
100% 100% 100% 100% 100%
xx xx xx xx xx
2012 2013 2014 2015 2016
Public Healthcare
Coverage
Private Coverage
6.3% 4.08% 5.1% 3.8% 2.2% 2.4% 3.6% GDP Growth (yoy)
14.7% 11.3% 15.5% 7.5% 4.2% NA NA HC Spend Growth (yoy)
Illustrative

45
5.2 Reimbursement Process
The reimbursement process in Australia healthcare system can be complex and can vary depending on the type of healthcare service,
the healthcare provider, and the insurance coverage. Here are the general steps involved in the reimbursement process:
▪ Service or Treatment Provided: The healthcare provider performs a service or treatment for the patient
▪ Billing: The healthcare provider submits a claim to the insurance company or other payer, requesting reimbursement for the
service provided
▪ Adjudication: The insurance company or other payer reviews the claim to determine whether it meets the criteria for
reimbursement. This can involve verifying the patient's eligibility, reviewing the treatment provided, and checking for any potential
errors or fraud
▪ Payment: If the claim is approved, the insurance company or other payer reimburses the healthcare provider for the service
provided, based on the negotiated payment rates or fee schedule
▪ Patient Responsibility: Depending on the patient's insurance coverage, they may be responsible for paying a portion of the cost
of the service, such as deductibles, co-payments, or co-insurance
In order to obtain access to all of the information that you are seeking, you will need to purchase the final report
Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the
topic or subject matter of interest
Illustrative

46
5.2 Reimbursement Process (Continued)
The reimbursement process in Australia healthcare system can be complex
and can vary depending on the type of healthcare service, the healthcare
provider, and the insurance coverage. Here are the general steps involved
in the reimbursement process:
▪ Service or Treatment Provided: The healthcare provider performs a
service or treatment for the patient
▪ Billing: The healthcare provider submits a claim to the insurance
company or other payer, requesting reimbursement for the service
provided
▪ Adjudication: The insurance company or other payer reviews the claim
to determine whether it meets the criteria for reimbursement. This can
involve verifying the patient's eligibility, reviewing the treatment
provided, and checking for any potential errors or fraud
▪ Payment: If the claim is approved, the insurance company or other
payer reimburses the healthcare provider for the service provided,
based on the negotiated payment rates or fee schedule
MoH
Private Payers Public Payers
Health Technology Assessment
Payment
Coverage
Coding
Coding depends on availability code while coverage and
payment process decisions are made through an HTA.
Market Authorization
1 3
2
Illustrative

6. Methodology & Scope

Insights10 is a healthcare focused market
research firm founded with an aim of being an
insights driven company in the data driven world
and delivering actionable insights that can drive
decision and strategy making process for
businesses
www.insights10.com
Life-sciences Market
Research Reports you
can trust
www.insights10.com

A large database of over 30,000 syndicated
market research reports in pharmaceuticals and
healthcare sector at global, regional as well as
country level. We also provide customized
research reports tailor made to suit your needs
Get actionable insights to
take informed business
decisions
www.insights10.com

Our qualitative, acute, and result-oriented market
research reports provide a comprehensive
understanding of the business scenario and the
latest trends related to the life-sciences market
Elevate your business plans
with in-depth market analysis
and industry intelligence
www.insights10.com

Whether you are looking to expand into new
areas, develop new products, or take advantage
of new opportunities we have reports to help you
accelerate and improve your plans by identifying
unique growth prospects.
Gain a competitive edge with
Insights10's customized
healthcare research solutions
www.insights10.com

Healthcare
Services
Clinical
Trials
OTC &
Nutraceuticals
Pharma
(Diseases
& Drugs)
Digital
Health
Medical
Devices
across various categories
Market Research Reports
Rare
Diseases
www.insights10.com

FEATURED REPORS
across various categories
Free Sample Reports
www.insights10.com

1200+
Reports
Published
Annually
30000+
Life science
Market Research
Reports
22000+
Country
Specific
Reports
2000+
Rare & orphan
Disease
Reports
What makes us different?

Market Overview
Growth Drivers &
Growth Restraints
Market Segmentation
Market Opportunities Factors Driving Future Growth
Reimbursement Scenario
Policy & Regulatory
Landscape
Key Company Profiles
Epidemiology &
Disease type
Competitive Landscape
insights on
which our
reports are
based
1
2
3
4
5
6
10
9
8
7

Yearly Access
(Subscription)
Regulatory
Compliance
Competitive
Intelligence
Conference
Coverage
Full-Time
Engagement
Database
Service & KOL
Mapping
Primary
Research &
Interviews
Customized
Market Research
Reports
Syndicates
Market Research
Reports
Our Services

Research Projects Done
Over the years, we have developed an in-depth experience of executing
market analysis at global, regional & country specific level in life-sciences.
Our team has
conducted market
research across 62+
global markets in
America, Europe,
Middle East, Africa and
Asia Pacific regions

Our Research Process
01 03
02 04 05
Identification of
Data
Collection of
Data
Market
Dynamics
Collaboration
of Data
Verification &
Analysis

Statistical Databases
Data
Sources
We have access to multiple highly
reliable free and subscription data
sources. We have many years of
experience to understand which
sources are more dependable for what
and which to prefer for the reliable and
latest information.
Company Websites/Annual Reports
Trade Publications
Online Databases
Published Research Reports
Whitepapers
Press Releases of Key Market Players

What kind of data is presented
in our reports?
Our reports present data, which is:
The report is
prepared using a
proven methodology
and insightful
research
Reliable
The data is prepared
by a team of highly
qualified &
experienced research
analysts & vetted by
our local associates
Expert-verified
Allowing you to
confidently make
smarter business
and strategic
decisions
Real
Covers everything
you would need to
know about the
market including
market size,
competitive analysis
& much more
Comprehensive
You do not have to
be a market expert
to understand what
really is happening
on the market and
how it works
Easy to read

Research Methodology
▪ Insights10’s research methodology delves deeper into the market, covering the macro and micro aspects of the industry. We identify the
key growth drivers, opportunities, and restraints that might promote or hinder the future industry growth along with an expansive
overview of the competitive landscape to help our clients make informed strategic decisions
▪ We implement a mix of primary and secondary research for our market estimate and forecast. The secondary research forms the initial
phase of our study where we conduct extensive data mining, referring to verified data sources such as independent studies, government
and regulatory published material, technical journals, trade magazines, and paid data sources
▪ For forecasting, the following parameters are considered:
❑ Market drivers and restraints along with their current and expected impacts
❑ Technological scenario and expected developments
❑ End use industry trends and dynamics
❑ Trends in the consumer behavior
❑ Regulatory scenario and expected developments
❑ Current capacity and expected capacity additions up to 2030
▪ We assign weights to these parameters and quantify their market impacts using the weighted average analysis to derive the expected
market growth rate
▪ We appoint data triangulation strategies to explore different areas of the market. Our qualitative and quantitative assessments are time-
sensitive, reflecting the most recent value and volume of the market across regions
▪ All our estimates and forecasts are verified through exhaustive primary research with the Key Industry Participants (KIPs)
▪ Currency used in the report is the US Dollar (USD), with the market size indicated in USD million/billion (Mn/Bn)

Analysis Methodology
Our Analysis Methodology involves three critical stages:
Market Trends
Market Sizing &
Analysis
Data Triangulation &
Validation
Analysis &
Interpretation
Insights
Presentation &
Reporting
Market Data Analysis
& Statistical Model
Interpretation &
Presentation
Secondary
Research
Proprietary
Database
Data
Collection
Primary
Research

Data Triangulation & Data Validation
Bottom Up Approach
Summarization of revenue
generated from companies
to arrive at total market size
Revenue generated by products &
services offered by companies
Validation from
Primary Interview
Final
Market
Size
Top Down Approach
Final Market size break up to
rest of segmentation
Arriving at market size
of each segment
Validation from
Primary Interview
Final
Summary

Key Benefits for Stakeholders from this Report
Study provides an in-depth analysis of the market with current trends and future estimations to elucidate the imminent
investment pockets
Our tools provides stakeholders with a cohesive understanding of the industry outlook, considering the qualitative and
quantitative industry variables
Comprehensive analysis of factors that drive and restrict the market growth is provided
Comprehensive quantitative analysis of the industry from 2021 to 2030F is provided to enable the stakeholders to capitalize on
the prevailing market opportunities
Extensive analysis of the key segments of the industry helps understand the applications and technologies used globally
Our rigorous data collection, thorough statistical analysis and specialist assessments ensure that our clientele has a greater
understanding of the industry space, supply chain, price fluctuations, competitive landscape, and other vital factors

2022
2023-
2030
Report Attribute
Quantitative Units
Report Coverage
Customized Report
Pricing and purchase
options
Revenue in USD Million/Billion (Mn/Bn)
Market Overview, Market Size & Revenue Forecast,
Market Segmentation, Growth drivers and restraints,
Company Profiles, Competitive Landscape,
Regulatory Landscape, Future Opportunities
Report Customization (4 to 7 working days) with
purchase. We will provide you with data that is
currently not a part of our scope as a part of
customization
Avail customized purchase options to meet your
exact research needs
Details
Time Frame
Base Year for
Estimation
Forecast
Period

“The business decision-making process is no longer as straightforward
as it used to be. It requires insights generated at the right time, based
on reliable data interpreted in a nuanced manner for each market.
We at Insights10 are building the future of market research and are
committed to providing our clients with the right intelligence and
insights to make business decisions quickly and efficiently.
Insights10 is a unique platform that combines deep domain expertise,
nuanced data at a country and functional area level, and years of
experience working with some of the best organizations in the world,
generating insights that provides substantial competitive advantage.”
Dr. Purav Gandhi
Founder & CEO
Click to watch the YouTube
Video
CEO Speaks

Purav is a physician and an
entrepreneur with 12+ years of
experience in Healthcare & Life
Sciences industry spanning across
strategy, market access, health
informatics and RWE, digital health,
analytics and data science. Purav
studied medicine from Gujarat
University and also completed his MBA
from IIM-Kozhikode. Purav started his
career with Deloitte working on strategy
consulting engagements and also co-
founded ConvergeHealth by Deloitte.
Anish has 15+ years of
experience in management
consulting in the Life Sciences
sector, and has worked with
diverse multinational firms in
the US, India, Middle East and
APAC regions. His primary area
of interest is Customer and
Market Strategy, Market
Access, and Digital Health with
special focus on emerging
markets like Africa, Middle East
and APAC.
Dr. Purav Gandhi
Founder & CEO
Anish Swaminathan
Director
Leadership Team
Mukesh is an engineering graduate with
an MBA in Marketing. He is a seasoned
healthcare market research &
marketing professional with a
progressive experience of over 20
years in Life Sciences, Healthcare
services, Pharma and Medical Device
sectors. With an in-depth understanding
of primary research, he has conducted
hundreds of interviews of various
stakeholders in pharma & healthcare &
completed several research projects
across life sciences industry.
Ritu has over 6 years of experience in
strategy building, market assessments,
market sizing, and RWE for global MNC
healthcare & biopharma clients across
diff. markets (America, Europe, Africa,
APAC and Middle East). Her areas of
expertise include: Indentifying emerging
trends in life sciences industry,
Competitor landscape assessment,
Disease opportunity assessments etc.
She is a pro in secondary and primary
research with a deep domain expertise
in healthcare sector.
Mukesh Nayak
Head – Marketing & Research
Ritu Baliya
Engagement Manager

… and many more
Our Clients
Pi-SM
GmbH

What our clients say
I've had the pleasure of availing Insights10’s services several times, and I've
always been impressed by their expertise, professionalism, and dedication to
providing us with the highest quality data and insights. Whether one is looking to
launch a new product, expand into a new market, or better understand one's target
customers, Insights10 insures achieving the goals.
Their team of experts has a deep understanding of the healthcare industry, and
they use their knowledge to develop customized research solutions that meet the
specific needs of each client. I highly recommend Insights10 to anyone looking for
a reliable and experienced partner in healthcare market research. They're a
valuable asset to any company that wants to succeed in this dynamic sector.
Sid Panigrahy
Founder-CEO, MediGlobo Inc.,
(Healthcare - Group Company of Omi Holdings, Inc) Tampa, Florida (USA)

Dear Insights10 Team, I wanted to thank you all for the great work you conducted
producing the Kenya Medical and Diagnostic Laboratory Service Market Analysis.
The quality of the report was excellent, and you managed to complete it in record
time. I was also impressed by your quick turnaround on the topics discussed as a
follow up after the report's first version; you managed to gather the information
required, plus a very good analysis.
I will definitely consider working with you again if the opportunity arises, and will
not hesitate in recommending you to colleagues working in the field Thank you
again for your professionalism and team work. It was a pleasure working with you.
Lelio Marmora
CEO, The Management Lab, Geneva
Ex. Executive Director, UNITAID

Michael Blumberg Youssef Mallat
Wissem Menad
Dr. Robert Ryan
Co Founder GFAU Pty Ltd., Australia
Co Founder – Embi, Optimum Oral care, Australia
Opusline, A part of Accenture, Paris
Senior Manager Segment Marketing
Performance Health, London, UK
Chief Executive Officer, Innova Therapeutics, Inc., USA
We engaged INSIGHTS10 to assist us with our research requirements
for the Oral Care Market sector in Australia. We been very impressed
with the depth and quality of data and equally with the personal
service we experience from the management team on our account.
They understand our business, our challenges and our goals. There is
a real sense of partnership as we continue to work together.
The info you delivered on the European Patient
Support Market with a deep dive into countries
like Spain, Germany, Italy, Australia, UK and
Belgium, was very useful.
Insights10 has been a great resource for
getting a detailed report on the UK
Physiotherapy Market. Usually I had multiple
sources for getting global reports, but now I
can get in-depth country reports from
Insights10 which has been a game changer.
We were looking for very specific information regarding Abu Dhabi
Oncology Drugs Market. The insights provided by Insights10 is
fantastic and they just took less than three days to deliver the report.

Thank you
www.insights10.com
Email: insights@insights10.com
India: (+91) 931 639 7935
Australia: (+61) 435 372 428
Whatsapp: (+61) 435 372 428
We would be happy to help.
Do you have
any questions?

Australia Dermatology Drugs Market

Recommended

Recommended

More Related Content

Similar to Australia Dermatology Drugs Market

Similar to Australia Dermatology Drugs Market (20)

More from Insights10

More from Insights10 (19)

Recently uploaded

Recently uploaded (19)

Australia Dermatology Drugs Market